Can the new nRF9151 kit from Nordic Semiconductor unlock direct-to-satellite IoT?
Nordic Semiconductor launches nRF9151 kit for satellite and cellular IoT. Find out how this innovation is changing IoT connectivity—read the full story now!
Novartis is buying its way into the next wave of genetic medicine — Avidity could be the entry point
Discover how Novartis’s proposed acquisition of Avidity Biosciences at over $70 a share could reshape its pipeline strategy and disrupt the rare-disease biotech space.
Pfizer just flipped the script on drug prices—now Eli Lilly and Amgen are ripping. Is this the start of a new pharma bull run?
Pfizer’s U.S. drug-pricing pact triggers a pharma relief rally. See what it means for Eli Lilly, Amgen, and investors today—read the data-driven outlook.
Flexiroam stock holds at A$0.007 as CFO appointment raises hopes for a microcap turnaround
Flexiroam (ASX: FRX) holds at A$0.007 as it appoints a new CFO. Find out how tighter finance and a global eSIM footprint could drive a microcap re-rating today.
Alcoa’s $890m blow: Why the Kwinana alumina refinery shutdown marks the end of an era in Australia
Alcoa (NYSE: AA) is shutting its Kwinana alumina refinery in Western Australia with an $890M charge. Explore the financial, market, and sector impact.
Why IDT Corporation is targeting $141m–$145m EBITDA in 2026 and what its AI-driven strategy means for investors
IDT Corp (NYSE: IDT) sets $141M–$145M EBITDA goal for 2026, banking on AI-driven growth in net2phone and remittances. Can it sustain momentum?
Progress Software raises FY2025 revenue guidance to nearly $1bn—what does it signal for investors?
Progress Software (NASDAQ: PRGS) lifts FY2025 guidance to $975M–$981M as AI adoption and ShareFile integration boost growth—see investor sentiment today.
Jimin’s Dior Paris Fashion Week comeback shows why K-pop idols now hold the keys to global luxury branding
Park Jimin returns at Dior’s Paris Fashion Week after military service—discover why his comeback matters for fashion, fandom, and global brand power.
Johnson & Johnson wins FDA approval for Tremfya in pediatric psoriasis and psoriatic arthritis
Johnson & Johnson wins FDA approval for Tremfya in pediatric psoriasis and psoriatic arthritis, extending its immunology lead and boosting growth prospects.
Why Kellanova shares jumped on reports Mars’ $36B deal could win EU approval
Kellanova shares surged as reports suggest the EU may approve Mars’ $36B deal. Discover what it means for investors, snacks, and competition.